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The objective of this paper is to present the process of the national and international accreditation leading to the establishment of the 
first certified chimeric antigen receptor T (CAR-T) Cell Unit in Poland on the basis of the Department of Hematology and Bone Marrow 
Transplantation in Poznan University of Medical Sciences and first successful CAR-T therapy in Poland. During 12 months from the initial 
decision to establish the CAR-T Cell Unit to the application of CAR-T cell treatment in the first patient, the center had to undergo the 
multidisciplinary external and internal training, as well as the adaptation of multiple procedures within the Transplant Unit and Stem 
Cell Bank. In order to get accreditation for the implementation of CAR-T cell therapy, an initial training of the team involved in handling 
cellular products and patient care was organized and updated as a continuous process. The Department fulfilled the site-selection 
international criteria. The first patient diagnosed for refractory/relapsed DLBCL was qualified, and finally CAR-T cells were administered 
with successful clinical outcome.
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Introduction
New insights into genetic characteristics of the cancer cell and progress 
in biotechnology have initiated the development of the chimeric antigen 
receptor T (CAR-T) cell therapy. Clinical studies are underway for 
multiple B-cell malignancies, including B-cell acute lymphoblastic 
leukemia, Hodgkin and non-Hodgkin lymphomas, chronic lymphocytic 
leukemia, acute myeloid leukemia, and multiple myeloma. However, 
the most advance is seen in B-cell malignancies. Results from clinical 
trials have resulted in approval by European Medicines Agency in 
August 2018 of two first in class CAR-T cells, namely, tisagenlecleucel 
(Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Gilead/Kite) 
[1, 2, 3]. CAR-T cells that are used in the two approved products and 
in the most advanced clinical trials are directed against CD19 which is 
expressed on the surface of the vast majority of B cells, including B-cell 
malignancies.
CAR-T therapy involves ex vivo genetic manipulation of patient’s own 
T lymphocytes to create recombinant receptor with cell activating 
functions. After reinfusion, CAR-T cells penetrate tissues, amplify, and 
eliminate target neoplastic cells. In approved indications, the treatment 
leads to durable responses of up to 70%; however, unique profile of 
toxicities requiring specific therapy may be observed. Centers willing 
to administer CAR-T cell therapy should have an experience that 
guarantees safety of treated patients and be able to go through high-
quality accreditation procedures.
The objective of this paper is to present process of national and international 
accreditation leading to the establishment of the first certified CAR-T Cell 
Unit in Poland on the basis of the Department of Hematology and Bone 
Marrow Transplantation in Poznan University of Medical Sciences and first 
successful therapy with CAR-T cells in Poland.
Material and Methods
Legal background
Presented data are based on the experience and knowledge from 
accreditation process for CAR-T cell therapy organized by Gilead/Kite, 
Novartis and Janssen in our center, European guidelines, Poltransplant 
and National Centre for Tissue and Cell Banking guidelines, and Polish 
law [4].
Center and patients
Process of arrangements of the center to the accreditation and 
implementation of CAR-T cell therapy was based on the following 
activities:




4. CAR-T cells administration
5. Management of CAR-T cells toxicity and patient safety.
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Initial education of team involved in handling cellular 
products and patient care
Highly specialized CAR-T technology requires cooperation of the 
multidisciplinary team consisting of laboratory team handling with 
cellular products, clinical team including physicians, and nurses 
from different departments who are all responsible for patient care. 
Initial education is necessary and it is based on both the international 
experience and the local hospital principles of the management of 
the patient.
Site selection
The intense immune activation results in severe adverse reactions 
which need to be managed appropriately to allow successful and safe 
clinical use of CAR-T cells. A 24/7 on-call service must be provided 
by a highly specialized team consisting of experienced physicians 
trained in allogeneic stem cell transplantation and intensive care. 
Relevant experience is associated with carrying out of at least 120 
allogeneic transplantations over the past 3 years. The transplant 
team is complemented by neurologists and radiologists specifically 
trained for CAR-T cell patient care. To minimize the risk associated 
with CAR-T cells treatment, there must be an immediate access 
to four doses of tocilizumab for each patient as cytokine release 
syndrome (CRS) management medication prior to treating patients.
Each site that is qualified for CAR-T cells treatment must have 
established procedures:
1.  Facilitating identification, monitoring, and treatment of CRS and 
serious neurological adverse reactions.
2.  Ensuring that adverse reactions are adequately and appropriately 
reported.
3.  Ensuring that detailed instructions about the storage and thawing 
procedure are provided.
Site must have access to the apheresis center which is capable 
to collect autologous lymphocytes and ship for further processing 
into dedicated laboratories. Hospital must also have an access 
to appropriate facility that provides storage adequate to the 
manufacturer’s expectations (vapor phase of liquid nitrogen below 
150°C). Since the CAR-T is formally the drug, storage and thawing 
must be under the supervision of a trained pharmacist. At every step, 
identification of the product (both autologous lymphocytes and the 
final CAR-T) with the patient is a crucial point of the whole process 
and needs to be performed independently by two staff members 
called “four eyes principle.”
An additional but important element of the site selection is the 
availability of patients, which aims at the optimal, cost-effective use 
of expensive and complicated procedures such as CAR-T cells.
Patient’s qualification
The administration of CAR-T cells is a complex and costly endeavor 
involving cell manufacture, shipping of apheresis products, and 
management of novel and severe adverse reactions. The use of 
CAR-T cells demands not only highly qualified multidisciplinary team 
but also an optimal patient selection.
For Yescarta the indications are diffuse large B-cell lymphoma 
(DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell 
lymphoma, transformed follicular lymphoma after two or more lines 
of systemic therapy. Indications for Kymriah include DLBCL, high-
grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. 
Separate population for Kymriah are pediatric and young adults 
up to 25 years of age with B-cell ALL that is refractory, in relapse 
posttransplant or in second or later relapse.
Patients receiving Yescarta or Kymriah should be deemed by their 
physician to have adequate organ function and performance status to 
tolerate the therapy. It is recommended, but not mandatory, to have 
tumors that are positive for the CAR-T target (CD19). Patients should 
have an adequate number of T cells for collection. The threshold for 
an absolute lymphocyte count varies from the manufacturers, but it is 
usually above 0.1 G/l.
Patients with an active central nervous system (CNS) disorder or 
inadequate renal, hepatic, pulmonary, or cardiac function are likely 
to be more vulnerable to the consequences of the adverse reactions 
and require special attention. CAR-T cells should not be administered 
to patients with an active infection or inflammatory disease until 
this condition has been resolved. HBV reactivation, in some cases 
resulting in fulminant hepatitis, can occur in patients treated with 
drugs directed against B cells. Screening for hepatitis B virus (HBV), 
hepatitis C virus (HCV), and human immunodeficiency virus (HIV) 
should be performed in accordance with clinical guidelines before 
collection of cells for manufacturing of CAR-T.
The experience of use of CAR-T cells in patients with primary or 
secondary CNS lymphoma is limited and thus the risk/benefit has 
not been established in this population. The pregnancy status of 
women of child-bearing potential must be verified before starting 
the treatment. There are no available data in pregnant women. No 
reproductive and developmental toxicity animal studies have been 
conducted; thus, it is difficult to assess whether it can cause fetal 
harm when administered to a pregnant woman. Formally, CNS 
involvement and pregnancy are contraindications for CAR-T cell 
therapy [5].
CAR-T cells administration
CAR-T products must be administered in a qualified clinical setting 
and supervised by a physician experienced in the treatment of 
hematological malignancies and cellular therapy. The availability of 
Yescarta or Kymriah must be confirmed prior to lympho-depleting 
regimen. Lympho-depleting chemotherapy is recommended during 
2 weeks prior to the administration of CAR-T cells. The most 
common regimen used is fludarabine-cyclophosphamide; however 
bendamustin might be considered in selected patients (for Kymriah) 
[5].
Prior to the infusion of CAR-T cells, the availability of tocilizumab 
and emergency equipment must be confirmed. For premedication, 
paracetamol by oral and diphenhydramine by oral or intravenous 
administration is recommended. Corticosteroids should be avoided 
as it may interfere with the activity of CAR-T cells. After patient and 
product verification, CAR-T cells are being thawed in a sterile bag 
at 37°C in a water bath (or by dry thaw method) within 3–5 minutes. 
Once thawed, the product is stable for 3 hours in a room temperature. 
Both Yescarta and Kymriah must be administered via intravenous 
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infusion through central venous catheter. Infusion that takes up to 
30 minutes is performed via no leuko-depleting filter tubing filled with 
0.9% NaCl.
Patient safety issues and management of CAR-T toxicity
Administration of CAR-T cells is associated with the risk of 
immunological (cytokine release syndrome (CRS)), neurological 
(immune effector cell-associated neurotoxicity syndrome (ICANS)), 
and hematological (lymphopenia, neutropenia) complications, 
leading to the risk of metabolic (tumor lysis syndrome) and infectious 
complications including septic shock and risk of patient transfer to 
intensive care unit. According to international guidelines, during 
process of CAR-T cell therapy, patient should be continuously 
monitored for these complications [4, 5]. Antimicrobial prophylaxis is 
mandatory.
Results
Initial education of team involved in handling cellular 
products and patient care
At the end of 2018, just after registration of the first in class CAR-T 
cell products by the European Medicines Agency (EMA), the 
CAR-T multidisciplinary team, including physicians, nurses, and 
coordinators from the Bone Marrow Transplant Unit, the Stem Cell 
Bank, the Intensive Care Unit, consultant neurologists, and Hospital 
Pharmacy, was established in our hospital. The process of internal 
and external training was started. Additionally, Departments of 
Pathology, Radiology, and Microbiology were informed and educated 
regarding the principles of the planned therapy.
Site selection
The Poznan CAR-T Cell Unit rose in 2019 as a part of the Transplant 
Unit, founded in 1990. So far we did perform over 2000 stem cell 
transplants, including approximately 960 allogeneic ones (130 stem 
cell transplants per year including 70 allogeneic ones). Transplant 
physicians, qualified nurses, transplant coordinators do work together 
with multidisciplinary team of specialists including neurologists, 
cardiologists, pneumologists, dermatologists, surgeons, intensivists, 
and others. The Apheresis Unit, which is a part of the Transplant Unit, 
does perform over 300 procedures yearly. The Unit is accredited by 
Ministry of Health for both allogeneic and autologous stem cell and 
lymphocyte collection. After cell collection the apheresis product is 
received by Stem Cell Bank, accredited by Ministry of Health. The 
qualified staff, with many years banking experience, prepares 700 
cellular products per year. The Stem Cell Bank is a perfectly organized 
structure cooperating with central, hematological (especially flow 
cytometry), and microbiological laboratories. Our bank cooperates 
with other national and international transplant centers. The 
activity of Stem Cell Bank according to national (composed on 
EU) requirements is confirmed by Ministry of Health accreditation. 
It works in accordance with ISO 9001:2015 standard. For CAR-T 
program quality assurance system, arising from requirements related 
to hematopoietic cell transplantation was implemented.
Patient’s qualification
In our center, the qualification of patient is performed by the 
transplant team during transplant qualifications. The transplant 
team includes eight physicians who are experienced in cellular 
therapy (average experience >10 years). Qualification form includes 
information regarding diagnosis with histopathology/cytology results, 
disease stage, previous treatment, performance status according to 
World Health Organization (WHO), risk of the procedure measured 
by Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). 
Final qualification is made based on the additional tests such as 
complete blood count, biochemistry, infectious diseases markers, 
cardiology assessment, magnetic resonance imaging (MRI) of CNS, 
positron emission tomography–computed tomography (PET-CT) 
scan. Patients who are not accepted for CAR-T cell therapy are 
advised to other treatment, including stem cell transplantation or 
clinical trials.
According to the standard guidelines, the patient qualified for CAR-T 
therapy, after reassessment (disease staging; infectious disease 
markers are valid for 30 days), undergoes leukapheresis. After 
verification with “four eyes principle”, the apheresis product is under 
care of the Stem Cell Bank which is responsible for the assessment 
of the product, processing depending on the product (deep freezing 
for Kymriah), and shipping of the product to the manufacturer. The 
reception of the commercial CAR-T products (Yescarta or Kymriah) 
is provided by Hospital Pharmacy, which handle the products over 
to the Stem Cell Bank for storage, final packing, and transportation 
before administration. An agreement between Pharmacy and Stem 
Cell Bank confirms the responsibility of the pharmacist for the product 
identification, storage, and appropriate thawing.
CAR-T cells administration
In our hospital, CAR-T therapy takes place in the Transplant Unit 
under supervision of the transplant physicians and qualified nurses. 
Before the start of the lymphodepleting chemotherapy detailed 
reassessment is performed, including disease staging, comorbidities, 
infection/inflammatory status (with infectious diseases markers), and 
cardiac assessment. As manufacturing of the CAR-T product takes 
up to 4 weeks, the patient may require bridging therapy which is also 
provided in our center.
Administration of the CAR-T product is performed as described 
earlier. CAR-T cells are not administered to patients with an active 
infection or inflammatory disease until this condition has been 
resolved. Patient is monitored daily for the first 10 days following 
CAR-T infusion for signs and symptoms of potential complications, 
especially CRS, neurological events, or infections. After the first 
10 days the patient can be discharged from the hospital; however 
the patient is instructed to remain within proximity to the hospital for 
at least 4 weeks following infusion. During the first 10 days, detailed 
assessment is performed daily which includes clinical, neurological 
(including neurocognitive testing), biochemistry, complete blood 
count, additional markers (ferritin, procalcitonin, C-reactive protein, 
troponin, NT-proBNP, immunoglobulins).
Outpatient management is focused on the treatment efficacy (PET-CT 
assessment) and potential complications (hypogammaglobulinemia, 
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prolonged neutropenia, infections, primary and secondary 
neoplasms).
First patient: treatment, safety, and management of 
CAR-T cell toxicity
The first patient, 24-year-old male with diffuse large B-cell lymphoma, 
not otherwise specified (DLBCL NOS) (refractory, early relapse after 
autologous stem cell transplantation), was qualified to therapy with 
axicabtagene ciloleucel. The patient was in overall good condition 
(ECOG1) without CNS involvement. Autologous T lymphocytes were 
obtained via apheresis on October 25, 2019 and underwent the 
genetic modification in dedicated laboratory in USA. Yescarta was 
shipped from the manufacturer to our Pharmacy/Stem Cell Bank in 
cryopreserved form. After leuko-depletion with cyclophosphamide 
and fludarabine the first in Poland CAR-T cell infusion was performed 
after thawing of the product on November 28, 2019 at the Transplant 
Unit. The infusion was well tolerated. Post-infusion period was 
complicated by leukopenia and neutropenia; however, the patient 
was afebrile and CRS/ICANS symptoms did not occur. The patient 
was discharged from the hospital at day +14 after infusion in good 
condition with improvement in disease in interim assessment.
Discussion
During 12 months from the initial decision of creation of the CAR-T 
Cell Unit to the application of CAR-T cell treatment to the first patient, 
our center had to undergo multidisciplinary external and internal 
training, as well as adaptation of multiple procedures within the Stem 
Cell Bank and Pharmacy.
In order to get accreditation for CAR-T cell therapy, an initial training 
of the team involved in handling cellular products and patient care 
was organized and updated as continuous process. The Department 
fulfilled the site-selection international criteria. The first patient 
diagnosed for refractory/relapsed DLBCL was qualified, and finally 
CAR-T cells were administered.
The three critical issues were as follows:
1. Creation and training of multidisciplinary team
2.  Adaptation of multiple procedures to the new international 
requirements
3. The safety of patient during and after CAR-T cell infusion.
There is a number of complications seen after CAR-T cells therapy 
[5, 6]. The most common is CRS, observed in more than 90% patients; 
however, grades 3–4 are seen in about 11% patients with fatal 
events below 3%. The most typical symptoms include fever, hypoxia, 
hypotension, and organ toxicity. It is an early complication occurring 
usually in the first week after treatment, with median duration of 
7 days. Neurological complications (ICANS) are diagnosed in up to 
67% of patients, with grades 3–4 in 32% patients. Clinical picture 
include encephalopathy, headache, tremor, dizziness, aphasia, and 
seizures. Most of the neurological symptoms are transient and fully 
reverse with 3–4 weeks. The mortality with ICANS is currently <4%. 
Febrile neutropenia and infectious complications have rather mild 
to moderate course; however they are related to severity of CRS. 
Other toxicities observed after CAR-T cell therapy include tumor 
lysis syndrome, hypersensitivity reactions, prolonged neutropenia, 
hypogammaglobulinemia, and secondary malignancy. Management 
of the CAR-T toxicities is described elsewhere [4, 5, 6].
In conclusion, with the effort of dedicated personnel from 
multidisciplinary team, including handling of cellular products and 
taking care of patient, we were able to overcome existing issues and 
barriers.
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